Prediction and Diagnosis: Application of Biomarkers for Bone Metastasis
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Omics/Informatics".
Deadline for manuscript submissions: closed (10 April 2023) | Viewed by 9278
Special Issue Editors
Interests: osteosarcoma; bone tumor; bone metastasis; artificial intelligence; tumor models; PDX; organoid
Interests: osteosarcoma; bone tumor; bone metastasis; artificial intelligence; tumor models; PDX; organoid
Interests: osteosarcoma; bone tumor; bone metastasis; tumor models; PDX; organoid
Special Issue Information
Dear Colleagues,
Bone is one of the most prevalent metastatic sites of many solid tumors. Cancer spread to the skeleton can result in multiple skeletal-related events (SREs), including systemic hypercalcemia, bone pain, pathological fracture, or paraplegia caused by spinal cord compression. Mechanistically, cancer cells interact with other cells in the bone microenvironment to activate a “vicious cycle”, leading to disruption of bone integrity and facilitating bone metastasis. Given the increased osteoclast activity and bone destruction, bone metastasis may impose a major clinical challenge affecting patient quality of life and contribute to considerable medical cost. Recent studies on the tumor biology and clinical significance of bone metastasis have identified novel predictive and diagnostic biomarkers as well as therapeutic targets. Emerging therapies targeting these biomarkers or signaling pathways may shed light on treating bone metastasis or preventing the formation of overt metastasis in the future. For instance, tartrate-resistant acid phosphatase type 5b (TRACP-5b) is mainly secreted by activated osteoclast and identified as the most accurate marker for bone metastasis in postmenopausal patients with luminal-type invasive ductal carcinoma. Changes in its activity are found to be significantly correlated with the treatment efficacy of bisphosphonates, implicating its potential in evaluating the antitumor effect in breast cancer bone metastasis. More recently, the advancement of artificial intelligence (AI) has facilitated the application of novel biomarkers in bone metastasis. A variety of deep learning models have been developed and applied in automatically analyzing or segmenting bone metastasis with high accuracy, which merits further exploration in the near future.
This Special Issue aims to determine the state of art of biomarkers for precise prediction and early diagnosis for bone metastasis caused by different solid tumors and find the respective countermeasures for different situations. In addition to existing conventional approaches, other effective strategies, such as AI-aided diagnosis, are urgently needed in bone metastasis.
We welcome the submission of original research and review articles including but not limited to basic research, clinical research, development and application of translational medicine, concise or systemic reviews, meta-analyses, commentaries, and viewpoints, on the following themes:
- New understanding of bone metastasis;
- Specific predictive or diagnostic biomarkers for the occurrence and development of bone metastasis;
- Signaling pathway targeting bone metastatic niche;
- Novel molecular mechanisms involved in bone remodeling;
- The application of artificial-intelligence-assisted precise prediction and diagnosis of bone metastasis.
Dr. Chao Tu
Dr. Haomiao Li
Dr. Hongwei Wu
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- bone metastasis
- solid tumors
- biomarkers
- exosome
- ncRNAs
- prediction
- diagnosis
- artificial intelligence
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
